all report title image
  • Published In : Jul 2024
  • Code : CMI2751
  • Pages :166
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Size and Trends

Global regulatory affairs outsourcing market is estimated to be valued at USD 8.41 Bn 2024 and is expected to reach USD 17.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031.

Regulatory Affairs Outsourcing Market Key Factors

To learn more about this report, request a free sample copy

Regulatory compliance is becoming more and more important with increasing regulations and the market is witnessing significant growth due to rising outsourcing of regulatory functions by medical device and pharmaceutical companies.

Growing clinical trial activities and new product launches can boost demand for outsourcing regulatory services. Moreover, increasing stringent regulatory standards prompt life sciences companies to rely more on specialist regulatory consultancies for ensuring compliance.

Increasing Stringent Government Regulations

With the rapid development of new technologies, drugs and medical devices, regulatory frameworks and guidelines have become more complex and stringent. Pharmaceutical and biotech companies are finding it challenging to continuously keep track of the dynamic regulatory landscape and ensure compliance at all stages of product development and marketing. The approval processes have become lengthier with increased data requirements. Any oversight can delay the launch of new products and hinder business operations. Outsourcing regulatory work allows companies to leverage the dedicated expertise of specialized providers that continually monitor changes in regulations. This helps them navigate the complex compliance requirements more efficiently and mitigate risks of non-compliance. Subject matter experts at outsourcing firms keep abreast of the evolving guidelines through constant research and stakeholder interactions. These can proactively guide companies and ensure all submissions meet current standards, thus, accelerating approval timelines. Outsourcing non-core regulatory functions frees up internal resources that can be better utilized to focus on strategic business priorities.

Market Concentration and Competitive Landscape

Regulatory Affairs Outsourcing Market Concentration By Players

To learn more about this report, request a free sample copy

Demand for Local Representation

With rise of new markets globally, companies increasingly aim to expand into international geographies. However, regulatory compliance and product approval processes differ widely across countries and regions due to variances in local healthcare systems, policies, and cultural contexts. Meeting individual country-level requirements requires in-depth knowledge of local regulations as well as infrastructure like facilities and personnel on-ground. This poses organizational challenges for multinational corporations managing global operations. Regulatory outsourcing provides them access to dedicated country experts who understand local regulatory nuances. Outsourcing partners establish local offices and hire native representatives who can directly liaise with the relevant authorities on their behalf. These ensure that all documentation for approval is exactly as per the local filing standards. This eases market entry by effectively navigating domestic complexities and expediting approvals. Companies can leverage outsourcers' existing set-up across various regions to augment their international presence without the need for separate investments. Local outsources partners play an instrumental role in helping life sciences firms expand into new high potential markets worldwide.

Key Takeaways from Analyst:

Global regulatory affairs outsourcing market is expected to witness growth. North America currently dominates the market due to stringent regulations around drug development and medical devices. However, Asia Pacific is expected to be fastest growing region due to lower costs and growing in-house capabilities of regulatory service providers (RSPs) in the region.

The market growth is driven by biopharma industry's need to focus on core competencies and cost savings achieved through outsourcing regulatory work. Navigating the complex regulatory landscape requires specialized expertise that most companies lack internally, thus, boosting need to engage external experts. Compliance requirements are also becoming more complex due to global nature of clinical trials and product registrations.

Data privacy and information security concerns can hamper the market growth. Regulatory submissions involve exchange of critical product information and compliance data, which needs robust protection. However, outsourcing reduces control over intellectual property and compliance strategies. Changing regulations and disruptions like the COVID-19 pandemic increase uncertainty.

Companies are increasingly demanding value-added and strategic services like regulatory intelligence, strategy advisory and end-to-end submissions management.

Market Challenges: Data security issues

Data security issues can hamper the global regulatory affairs outsourcing market growth. Regulatory affairs outsourcing involves sharing of sensitive information such as intellectual property, clinical trial data, product approval strategies and compliance documents with outsourcing companies. Any breach of data security can compromise such sensitive information and harm the business and reputation of pharmaceutical/medical device companies. With increasing number of cyber threats and data breaches, companies have become more cautious about data sharing. Several incidences have been reported, where regulatory documents were leaked or stolen due to poor data security of outsourcing companies. For instance, according to a report published by U.S. Food and Drug Administration in 2021, few biotech startup companies faced regulatory delays and monetary losses after their product approval documents were compromised from outsourcing company servers. This eroded customer confidence in outsourcing. Furthermore, strict data localization and residency laws in many countries discourage cross-border data sharing. Companies located in jurisdictions like China are especially a high risk from data security perspective. The growing data privacy regulations worldwide have also increased compliance requirements for outsourcing companies to strengthen their data security infrastructure and practices.

Market Opportunities: Adoption of new technologies like AI

Rising use of advanced technologies like artificial intelligence (AI) and machine learning (ML) can offer regulatory affairs outsourcing market growth opportunities. These tools have the potential to revolutionize how compliance work is done - making workflows more efficient, automated and data-driven. AI can analyze huge volumes of documents, data and files much faster than humans. It can help accelerate regulatory document drafting, submissions management, labelling changes and stay updated with global regulatory changes instantly. This could free up regulatory professionals to focus more on high-level strategic work rather than routine tasks. Implementing AI technologies requires significant resources and expertise. However, regulatory outsourcing firms are well positioned to lead this transition due to their scale of operations, technical know-how, and access to global talent. By investing in new technology hubs and skill development, companies can build comprehensive AI-driven regulatory solutions and platforms. This will allow them to offer more specialized services and take on larger work portfolios from biotech and pharmaceutical clients. As regulation becomes more complex across sectors like healthcare, consumer goods, IT and energy due to geopolitical factors, there will be huge demand for digital transformation.

Regulatory Affairs Outsourcing Market By Service Type

To learn more about this report, request a free sample copy

By Service Type - Expertise and Experience Boosts Demand for Regulatory Consulting

In terms of service type, regulatory consulting and legal representation segment is estimated to contribute the highest market share of 25% in 2024, owing to the need for specialized expertise. Providing regulatory consulting and legal advice involves intricate knowledge of the ever-changing rules and regulations that govern clinical research and product approval processes. It also requires experience navigating the complex submission requirements and guidelines of health authorities. For many companies, especially small to mid-sized biotechs and medtech firms, it is not feasible to build and maintain an in-house team with the breadth of regulatory know-how needed across multiple jurisdictions. Outsourcing to specialized regulatory consultancies allows companies to leverage the expertise of regulatory professionals who do this work day-in and day-out. Consultants stay up-to-date on the latest policy changes and recommendations of agencies like the FDA and EMA. These can efficiently guide sponsors through regulatory procedures and help interpret agency feedback. Using external advisors also provides an unbiased perspective separate from internal pressures or politics. This is particularly important for legal evaluations and negotiations with regulators. The consultative services help minimize compliance risks and keep development programs on the most expeditious approval path. For large pharmaceutical firms, regulatory consulting provides surge capacity and additional geographic coverage without requiring new hires. Mid-sized and start-up biotechs rely on consultants for their very ability to navigate global approval processes and bring important new therapies to patients. As the regulatory landscape grows ever more complex, there will be huge demand for advisory services that distill expert regulatory knowledge into actionable guidance.

By End User, Pharmaceutical Companies contributes the highest share of the market owing to their extensive regulatory requirements

By end user, pharmaceutical companies segment is estimated to contribute the highest market share of 50% in 2024, face some of the most stringent regulatory requirements compared to other industries in the healthcare sector. Given the critical nature of drugs and their potential safety impacts, pharmaceutical products need to undergo rigorous clinical trials and obtain numerous regulatory approvals before these can be commercialized. Compliance with regulations is a complex process that requires dedicated expertise across multiple domains such as clinical research, product registration, safety monitoring, and compliance. The regulatory landscape also continuously evolves with new guidelines being issued. Managing regulatory requirements internally requires significant investments in building and continuously updating internal regulatory capabilities. For pharmaceutical companies, non-compliance with regulations can lead to delays in product approvals, rejection of applications, financial penalties, and even withdrawal of approved products in some cases. Given the high stakes, most pharmaceutical companies prefer to outsource their regulatory requirements to specialized contract research organizations that have deep regulatory expertise.

By Stage - Clinical contributes the highest share of the market

By stage, clinical segment is estimated to contribute the highest market share of 50.5% in 2024. Clinical testing is a critical stage in the drug and device development process that involves several regulatory requirements. Once a product enters clinical trials, the developer needs to comply with extensive regulations across areas such as trial protocols, safety monitoring, informed consent processes, data management and reporting. Dependable execution of clinical trials as per global regulatory standards is important to demonstrate a product’s safety and efficacy profile. However, designing and managing clinical programs as per constantly evolving guidelines requires substantial expertise that most industry players lack internally. Even larger companies find it difficult to have capabilities for all geographic and therapeutic regions. Non-compliance during clinical trials can delay further development and even risk trial sanctions. Given the costs and stakes involved, developers increasingly prefer to outsource clinical trial activities and associated regulatory functions. Outsourcing to specialized clinical research organizations with global regulatory capabilities allows them to stay focused on product development while ensuring compliance. It also provides access to a global network of investigators and sites. Many regulations require local representation and understanding of cultural sensitivities for trials conducted in international regions. Regulatory service providers help bridge these barriers by providing globally distributed resources with local expertise.

Regional Insights

Regulatory Affairs Outsourcing Market Regional Insights

To learn more about this report, request a free sample copy

North America dominates the regulatory affairs outsourcing market with an estimated market share of 40.2% in 2024. With the presence of well-established pharmaceutical companies and robust regulations, North America accounted for over 35% of the global market share in 2021. The region is home to major hubs like U.S. and Canada that boosts demand for outsourcing regulatory functions. Stringent regulations such as FDASIA have necessitated companies to rely on specialized regulatory service providers for ensuring compliance. Presence of leading contract research organizations (CROs) offering end-to-end regulatory solutions drives the market growth. Furthermore, high concentration of clinical trials in this region increases the need for regulatory expertise.

Asia Pacific region is poised to be the fastest growing market during the forecast period. Countries like China, India and Japan are emerging as global sourcing destinations for regulatory affairs due to increasing investments in healthcare infrastructure and pharmaceutical manufacturing capabilities. Supportive government policies promoting the life sciences industry coupled with availability of low-cost regulatory skilled resources are encouraging companies to establish regional hubs in Asia. Rising preference for Asia Pacific CROs owing to their comprehensive capabilities and localized expertise can boost outsourcing activity in this region. In addition, Asia Pacific companies are actively enhancing their global regulatory networks to cater growing international marketing authorizations for their products. While pricing of services is relatively lower compared to mature markets, the region offers high future growth potential backed by improving quality standards.

Market Report Scope

Regulatory Affairs Outsourcing Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 8.41 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 10.7% 2031 Value Projection: US$ 17.10 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Service Type: Regulatory Consulting and Legal Representation, Product Registration and Clinical Trial Applications, Regulatory Writing and Publishing, Regulatory Submission, Regulatory Operations, Others
  • By End User: Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies
  • By Stage: Preclinical, Clinical, PMA (Post Market Authorization)
  • By Therapeutic Area: Oncology, Neurology, Cardiology, Immunology, Others 
Companies covered:

Accell Clinical Research, LLC, Genpact, CRITERIUM, INC., PRA Health Sciences, Promedica International, WuXiAppTec, Medpace, PPD Inc., Charles River Laboratories, ICON plc, Covance, Parexel International Corporation, Freyr, Navitas Clinical Research, Inc., Medelis, Inc., Sciformix, Tech Tammina, Acorn Regulatory Consultancy Services Ltd., BIOMAPAS, REGULATORY PROFESSIONALS, CompareNetworks, Inc.

Growth Drivers:
  • Increasing Stringent Government Regulations
  • Demand for Local Representation
Restraints & Challenges:
  • Data security issues
  • Language and cultural barriers

Key Developments

  • In January 2023, AmerisourceBergen Corporation, drug wholesale company and a contract research organization acquired PharmaLex Holding GmbH, a leading service provider in the life sciences industry, particularly noted for its expertise in regulatory affairs. This acquisition marked a substantial expansion of AmerisourceBergen's service offerings within a critical market.
  • In April 2022, VCLS partnered with EC Innovations, a Chinese company specializing in global translation services. With a strong background in translating highly regulated life sciences and medical content, this collaboration significantly enhanced VCLS's capabilities and operational strengths.
  • In February 2021, ICON plc, Clinical research organization company completed the acquisition of PRA Health Sciences, Inc. in a transaction valued at around USD 12 billion, paid in cash and stock. This acquisition significantly bolstered ICON's capabilities in medical affairs services.
  • In August 2021, ProPharma Group , regulatory sciences consulting firm acquired iSafety Systems, Provider of end-to-end pharmacovigilance and safety servicesbased in India. This acquisition is anticipated to enhance ProPharma Group's global leadership in regulatory and compliance consulting, pharmacovigilance, clinical research services, and medical information.

*Definition: Regulatory Affairs Outsourcing Market provides regulatory services to help life sciences and medical device companies comply with the various regulatory requirements of health authorities globally. The services include assisting with the development and submission of documentation for approval of drugs, biologics and medical devices. Companies outsource their regulatory functions to specialized service providers to manage the complex regulatory environment more cost-effectively and focus internal resources on core business activities like R&D and commercialization. Outsourcing regulatory services allows companies to stay compliant with regulations and bring products to market faster.

Market Segmentation

  •  Service Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Regulatory Consulting and Legal Representation
    • Product Registration and Clinical Trial Applications
    • Regulatory Writing and Publishing
    • Regulatory Submission
    • Regulatory Operations
    • Others
  •  End User Insights (Revenue, USD Bn, 2019 - 2031)
    • Medical Device Companies
    • Pharmaceutical Companies
    • Biotechnology Companies
  •  Stage Insights (Revenue, USD Bn, 2019 - 2031)
    • Preclinical
    • Clinical
    • PMA (Post Market Authorization)
  •  Therapeutic Area Insights (Revenue, USD Bn, 2019 - 2031)
    • Oncology
    • Neurology
    • Cardiology
    • Immunology
    • Others
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Accell Clinical Research, LLC
    • Genpact
    • CRITERIUM, INC.
    • PRA Health Sciences
    • Promedica International
    • WuXiAppTec
    • Medpace
    • PPD Inc.
    • Charles River Laboratories
    • ICON plc
    • Covance
    • Parexel International Corporation
    • Freyr
    • Navitas Clinical Research, Inc.
    • Medelis, Inc.
    • Sciformix
    • Tech Tammina
    • Acorn Regulatory Consultancy Services Ltd.
    • BIOMAPAS
    • REGULATORY PROFESSIONALS
    • CompareNetworks, Inc.

Frequently Asked Questions

The CAGR of global regulatory affairs outsourcing market is projected to be 10.7% from 2024 to 2031.

Increasing stringent government regulations and demand for local representation are the major factors driving the growth of global regulatory affairs outsourcing market.

Data security issues and language and cultural barriers are the major factors hampering the growth of global regulatory affairs outsourcing market.

In terms of service type, regulatory consulting and legal representation segment is estimated to dominate the market in 2024.

Accell Clinical Research, LLC, Genpact, CRITERIUM, INC., PRA Health Sciences, Promedica International, WuXiAppTec, Medpace, PPD Inc., Charles River Laboratories, ICON plc, Covance, Parexel International Corporation, Freyr, Navitas Clinical Research, Inc., Medelis, Inc., Sciformix, Tech Tammina, Acorn Regulatory Consultancy Services Ltd., BIOMAPAS, REGULATORY PROFESSIONALS, CompareNetworks, Inc. are the major players.

North America is expected to lead the global regulatory affairs outsourcing market.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.